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INTRODUCTION
Drug-resistant tuberculosis (TB) is a global concern. 
However, the overall incidence of TB has been decreas-
ing slowly since 2004 because of the World Health Or-
ganization (WHO) efforts through the Stop TB Strategy 
[1]. Nevertheless, there is no definitive evidence that the 
incidence of multidrug-resistant (MDR) TB is decreas-
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Background/Aims: We evaluated the trend in the rates of drug-resistant tubercu-
losis (TB) over time, as well as the difference in the drug-resistance pattern be-
tween pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) at 
a private referral center in South Korea.
Methods: All patients with culture-confirmed TB from 2006 to 2013 were includ-
ed.
Results: In total, 1,745 patients were included: 1,431 (82.0%) were new cases, and 314 
(18.0%) were cases treated previously; 1,610 (92.3%) were diagnosed with PTB, and 
135 (7.7%) were diagnosed with EPTB. Multidrug-resistant (MDR) and extensive-
ly drug-resistant (XDR) TB were detected in 5.8% and 2.0% of new cases and in 
20.1% and 8.6% of previously treated cases, respectively. The MDR TB rate during 
the study period decreased remarkably, whereas the MDR and XDR TB rates de-
creased significantly in previously treated cases. No difference in the drug-resis-
tance rate was detected between PTB and EPTB.
Conclusions: The TB drug-resistance rate, particularly that of MDR TB, re-
mained high at a private referral hospital, and the drug-resistance rate did not 
decrease significantly from 2006 to 2013. This finding underscores the need for a 
national survey regarding the prevalence of drug-resistant TB to obtain the most 
accurate and current drug-resistance status in South Korea, including the private 
sector.
Keywords: Mycobacterium tuberculosis; Drug-resistance rate; Extrapulmonary 
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ing, despite this global effort [2]. Although considerable 
efforts in several countries, including South Korea, have 
led to a slow decrease in the overall incidence of TB, 
surveillance indicates that the incidence of drug-resis-
tant TB is rising [3-5]. Drug-resistant TB strains in South 
Korea account for 5.3% to 12.2% of new cases and 13.3% 
to 41.6% of previously treated cases, whereas MDR-TB 
strains account for 2.7% to 3.9% of new TB cases and 
14.0% to 27.2% of previously treated cases [3,6-8].
Drug-resistance is a critical determinant of treat-
ment success. Thus, to improve treatment success, the 
Mycobacterium tuberculosis drug-resistance pattern in 
community-based care should be determined. Despite 
geographical variations, a few studies have reported 
that drug-resistant TB occurs less often in cases of ex-
trapulmonary tuberculosis (EPTB) than in cases of pul-
monary tuberculosis (PTB) [9,10]. However, insufficient 
data are available regarding the current status of anti-TB 
drug-resistance in South Korea since 2008. Furthermore, 
there are no remarkable drug-resistance data for EPTB. 
Therefore, we evaluated the prevalence of drug-resis-
tance among M. tuberculosis isolates, as well as differenc-
es in the drug-resistance pattern among the M. tubercu-
losis isolates that cause PTB or EPTB.
METHODS
Study population and design
This study was conducted at Inje University Busan Paik 
Hospital (903-bed, university-affiliated, tertiary referral 
hospital in Busan, Republic of Korea). Isolates obtained 
from patients with a positive M. tuberculosis culture at 
Inje University Busan Paik Hospital from January 2006 
through December 2013 were included in this retrospec-
tive analysis.
This study identified trends in the resistance rates to 
anti-TB drugs among M. tuberculosis isolates recovered 
from patients diagnosed with TB over 8 years, which 
were determined using the proportional method [7]. We 
compared the drug-resistance pattern of M. tuberculosis 
isolates based on patient treatment history. In addition, 
we compared the drug-resistance pattern of M. tubercu-
losis isolates that cause PTB with those that cause EPTB.
Laboratory methods
Clinical specimens were cultured on 3% Ogawa medium 
(Shinyang, Seoul, Korea). The Mycobacteria Growth In-
dicator Tube 960 System (Becton Dickinson Co., Frank-
lin Lakes, NJ, USA) was introduced at our institution on 
January 1, 2009. Therefore, both solid and liquid media 
were used to culture mycobacteria beginning in 2009. 
All specimens were processed and pretreated, as recom-
mended previously [11]. All M. tuberculosis isolates were 
sent to the Korean Institute of Tuberculosis (KIT), a 
WHO-designated Supranational Reference Laboratory, 
for drug-sensitivity testing (DST). If multiple isolates 
were obtained from the same patient, only the first iso-
late was used for DST.
Resistance to anti-TB agents at the KIT is defined as 
mycobacterial growth in Lowenstein-Jensen medium > 
1% using the proportional method and observed at the 
following critical drug concentrations: isoniazid (INH), 
0.2 mg/mL; rifampicin (RFP), 40.0 mg/mL; rifabutin (Rfb), 
20.0 mg/mL; ethambutol (EMB), 2.0 mg/mL; streptomy-
cin (SM), 4.0 mg/mL; kanamycin (KM), 4.0 mg/mL; ami-
kacin (Amk), 4.0 mg/mL; capreomycin (CPM), 4.0 mg/
mL; ofloxacin (Ofx), 2.0 mg/mL; moxifloxacin, 2.0 mg/
mL; levofloxacin, 2.0 mg/mL; prothionamide, 40.0 mg/
mL; cycloserine (Cs), 30.0 mg/mL; and para-aminosali 
cylic acid, 1.0 mg/mL, respectively. Pyrazinamide (PZA) 
susceptibility was determined using the pyrazinamidase 
test [7].
Definitions
PTB was defined as TB involving the lung parenchyma. 
EPTB was defined as TB involving organs other than 
the lungs; e.g., pleura, without radiographic abnormali-
ties in the lungs, lymph nodes, abdomen, genitourinary 
tract, skin, joints and bones, or meninges and  with the 
confirmed presence of at least one M. tuberculosis speci-
men. A patient with both PTB and EPTB TB was classi-
fied as PTB [12].
Patients diagnosed with TB were classified into two 
groups according to their treatment history at the time 
of diagnosis: new cases included patients who had never 
received TB treatment or who had received treatment 
for < 4 weeks, and previously treated cases included pa-
tients who had taken anti-TB drugs for at least 4 weeks 
[13]. Moreover, previously treated cases were classified 
into three categories of relapse, treatment after failure 
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(TAF), and treatment after interruption (TAI). “Relapse” 
was defined as patients who had completed their treat-
ment but TB re-developed, “TAF” was defined as pa-
tients whose treatment had failed in the past but was 
resumed, and “TAI” was defined as patients with a treat-
ment history ≥ 1 month, along with a cessation period ≥ 
2 months [14].
The drug-resistance pattern was classified as follows: 
any drug-resistance was defined as resistance to any an-
ti-TB drug, monodrug-resistant TB was defined as resis-
tance to only one of the five first-line drugs (INH, RFP, 
EMB, PZA, and SM), MDR TB was defined as resistance 
to at least INH and RFP, and extensively drug-resistant 
(XDR) TB was defined as resistance to any fluoroquino-
lone and resistance to at least one of three injectable 
second-line drugs (AMK, CPM, and KM), in addition to 
MDR [13].
Statistical analysis
Results are presented as medians and interquartile 
ranges or as numbers (percentages). Continuous data 
were compared using the Mann-Whitney U test, and 
categorical data were compared with Pearson chi-square 
or Fisher exact tests. The drug-resistance trend over 
time was evaluated using the Cochran-Armitage trend 
test. All tests were two-sided, and a p < 0.05 was consid-
ered to indicate significance. Data were analyzed using 
IBM SPSS version 21 (IBM Co., Armonk, NY, USA).
Ethics statement
This study protocol was approved by the Institutional 
Review Board of Inje University Busan Paik Hospital. 
The requirement for informed consent was waived by 
the board.
RESULTS
The DST results of the M. tuberculosis culture isolates 
obtained from 1,745 patients during the 8-year study pe-
riod were analyzed for changes in drug-resistance pat-
terns (Table 1). Among the 1,745 TB cases, 1,431 patients 
(82.0%) had no history of TB treatment (new cases), and 
314 (18.0%) had a history of TB treatment for ≥ 1 month 
(previously treated cases). Of the 314 previously treated 
cases, 254 (80.1%), 48 (15.3%), and 12 (3.8%) were relapse, 
TAI, and TAF cases, respectively. Among the patients, 
1,610 (92.3%) had PTB, and 135 (7.7%) had EPTB (45 cas-
es of concurrent EPTB/PTB classified as PTB according 
to the definition). The most common disease site of the 
EPTB cases was the pleura, followed by the bones and 
joints. The median age of the patients was 54 years, and 
1,024 (58.9%) of the patients were male.
M. tuberculosis drug-resistance trend
Among the M. tuberculosis strains isolated from the 1,745 
patients, 1,406 (80.6%) and 1,423 (81.5%) were suscepti-
ble to all anti-TB drugs and all first-line drugs tested, 
respectively. Among them, 338 (19.4%), 321 (18.4%), 145 
(8.3%), and 55 (3.2%) were any-drug-resistant, monod-
rug-resistant, MDR, and XDR TB, respectively. A trend 
analysis performed according to the drug-resistance pat-
tern classification did not show a decrease in the rates of 
any-drug-resistant TB, monodrug-resistant TB, or MDR-
TB, except XDR TB (Fig. 1). The drug-resistance patterns 
of all cases for each anti-TB drug are summarized in Ta-
ble 2. A significant decline in the drug-resistance rates to 
Table 1. Demographic and clinical characteristics of the pa-
tients diagnosed with tuberculosis from 2006 to 2013 (n = 1,745)
Characteristic Value
Age, yr 54 (37–70)
Male sex  1,028 (58.9)
New case 1,431 (82)
Previously treated case 314 (18)
Relapse 254 (80.1)
TAI  48 (15.3)
TAF 12 (3.8)
Pulmonary TB  1,610 (92.3)
Extrapulmonary TB 135 (7.7)
Pleural TB  64 (3.7)
Bone and joint TB  26 (1.5)
Lymphatic TB 12 (0.7)
Abdominal TB  11 (0.6)
Central nervous system TB  10 (0.6)
Genitourinary TB  6 (0.3)
Skin and soft tissue TB  4 (0.2)
Pericardial TB  2 (0.1)
Values are presented as median (interquartile range) or number 
(%). 
TAI, treatment after interruption; TAF, treatment after failure; 
TB, tuberculosis.
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PZA, CPM, KM, and Ofx was observed during the 8-year 
study period.
M. tuberculosis drug-resistance according to previ-
ous treatment status
According to previous treatment status, 1,191 new cases 
(83.2%) were susceptible to all anti-TB drugs, whereas 
68.5% (215/314) of previously treated cases were suscep-
tible to all anti-TB drugs. The resistance patterns to 
each anti-TB drug based on previous treatment status 
are summarized in Table 3. The previously treated TB 
cases had a higher rate of resistance to almost all an-
ti-TB drugs, except CPM and Cs, compared with that of 
new TB cases. In addition, patients with any-drug-re-
sistant TB, monodrug-resistant TB, MDR TB, and XDR 
TB were more likely to belong to the previously treated 
group. The resistance patterns to each anti-TB drug ac-
cording to previously treated cases of relapse, TAI, and 
TAF are summarized in Table 4. TAF and TAI cases had 
a higher rate of resistance to almost all anti-TB drugs, 
compared with that of the relapse cases.
A trend analysis performed according to previous treat-
ment status showed a significant decrease in the rates of 
MDR TB and XDR TB in the group of previously treated 
cases but not in the group of new cases (Fig. 2). Moreover, 
a trend analysis performed according to previously treat-
ed cases of relapse, TAI, and TAF showed a significant 
increase in the proportion of relapse and a significant 
decrease in the proportion of TAI cases. However, no 
marked change in the TAF trend was detected (Fig. 3). 
 
M. tuberculosis drug-resistance according to pulmonary/
extrapulmonary involvement and previous treatment 
status
The drug-resistance patterns to each anti-TB drug ac-
cording to PTB/EPTB and previous treatment status 
are summarized in Table 5. Of the 314 previously treat-
ed cases, 296 (94.2%) had PTB, and 18 (5.7%) had EPTB. 
Among the 296 PTB cases, 237 (80.1%), 47 (15.9%), and 12 
(4.1%) were relapse, TAI, and TAF cases, respectively. In 
contrast, 18 EPTB cases were almost relapse (94.4%), ex-
cept one. No significant difference was observed in the 
drug-resistance rate between PTB and EPTB based on 
previous treatment status.
M. tuberculosis drug-resistance to PTB according to age 
The highest prevalence of drug-resistance was observed 
in the 50 to 59 year age group among new patients with 
PTB (any drug-resistance, 20.3%; monodrug-resistance, 
18.5%; MDR, 8.6%; and XDR, 1.8%) (Table 6).
DISCUSSION
In this study, we investigated changes in TB drug-re-
sistance patterns and differences in the drug-resistance 
pattern among new and previously treated TB cases. In 
addition, we compared the prevalence of drug-resistant 
TB observed in patients with PTB with that observed in 
patients with EPTB. The major findings were as follows. 
The rates of MDR and XDR TB in the private referral 
hospital remained high, but a slow decrease over time 
was suspected, particularly for previously treated TB 
cases. This finding may have been affected by changes 
in the proportions of relapse and TAI cases over time. 
In addition, although we evaluated a small number of 
EPTB cases, no difference in the drug-resistance rate be-
tween cases of PTB and EPTB was detected.
Determining the change in the TB drug-resistance 
rate over time and its current status in a region or nation 
are essential to adequately administer anti-TB regimens 
and achieve treatment success. According to the annu-
al report of the Korea Centers for Disease Control and 
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Figure 1. Trends in resistance rates to anti-tuberculosis 
drugs among Mycobacterium tuberculosis strains recovered 
from all 2006 to 2013 cases.
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Prevention of 2012, 1,212 MDR TB cases were reported 
via the national TB monitoring system, which is a large 
burden in Korea despite a national effort [15]. Howev-
er, no information regarding whether these were new 
or previously treated cases is available, despite the fact 
that a TB treatment history is a potent risk factor for 
MDR TB [16]. In addition, the proportions of patients 
with any-drug-resistant or monodrug-resistant TB are 
also unknown. According to the most recently pub-
lished data regarding drug-resistance rates in 2009 in 
a public health center, the percentage of any-drug-re-
sistant TB strains was 12.6% of new cases and 20.0% of 
previously treated cases. In addition, the percentage of 
MDR strains was 2.8% of new cases and 8.5% of previ-
ously treated cases [17].
However, the number of TB cases treated in the pri-
vate sector has been increasing continuously and was 
90.4% in 2012, as assessed by the national TB moni-
toring system [15]. Several studies have analyzed the 
TB drug-resistance rate in the Korean private sector 
[3,6,17-21]. Unfortunately, no reported data are available 
regarding the drug-resistance rate in the private sector 
after 2009. Furthermore, patients diagnosed with MDR 
or XDR TB since 2011 must be hospitalized to prevent 
transmission of drug-resistant pathogens based on the 
revised Korean National Tuberculosis Control program. 
Therefore, a more accurate evaluation of the drug-re-
sistance rate among TB cases in private sector clinical 
settings and the trend in the drug-resistance rate among 
TB cases is needed.
Table 2. Trends in the resistance rates to anti-tuberculosis drugs among patients diagnosed with pulmonary and extrapulmo-
nary tuberculosis from 2006 to 2013
Drugs
% of resistant Mycobacterium tuberculosis strains
p value
2006 2007 2008 2009 2010 2011 2012 2013
No. of stains 171 217 213 235 232 271 194 212
Any drug-resistance   20.5 19.4  16.4 24.3  22.4 17.7  16.5 17.5 0.350
Monodrug-resistance   19.3 18.9  15.5  22.6  20.3 17.3 16 17 0.432
MDR     9.4  9.7   6.1   9.8  9.9  11.8  4.1   4.2 0.094
XDR  3.5 6   2.3    3.4  4.7 3  0.5   1.4 0.014
Isoniazid  13.5 15.7  12.7  18.3  18.5 15.1  14.4 14.6 0.833
Rifampicin  9.4 11.1 7.5  11.1  10.3 12.9  5.2  5.7 0.161
Rifabutin  7.6   8.8  5.2    6.8  7.8  9.6  4.6  4.7 0.316
Ethambutol  6.4   8.8  3.8   8.1  8.2   8.9  5.2   3.3 0.307
Pyrazinamide  7.6   7.4 3.3    5.1  3.4   3.3 3.1   1.9 0.001
Capreomycin  1.2   3.2  2.8   2.1  2.2  0.7 0  0.9 0.026
Kanamycin  1.8   4.6 2.3   2.1 3   2.6 0  0.9 0.039
Amikacina - 0  1.8   2.1  3.0   1.8 0  0.4 0.735
Streptomycin  7.6  5.5  5.2   6.4  5.2   4.4 3.1   6.6 0.326
Moxifloxacin  2.9   2.8  1.4    3.4  4.3   1.5 1   1.4 0.197
Levofloxacinb - - 0.9    3.4  5.2   1.5 1   1.4 0.172
Ofloxacin  4.1  4.1  2.3    3.4  5.6   1.5 1   1.4 0.023
Prothionamide  1.2   2.8 3.3  3  4.3   2.6  1.5   1.4 0.656
Cycloserine 0  0.5 0   0.9 3 0  0.5  0.5 0.558
PAS  2.3  6.5  1.9    3.8  7.3   5.2 3.1  2.8 0.957
MDR, multidrug-resistance; XDR, extensively drug-resistance; PAS, para-aminosalicylic acid.
aAmikacin sensitivity testing at the Korean Institute of Tuberculosis (KIT) began in October 2007.
bLevofloxacin sensitivity testing at the KIT began in 2008, as gatifloxacin was removed from many markets because of the dys-
glycemia risk in elderly subjects.
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According to previous studies performed in the pri-
vate sector based on TB strains identified before 2009 
[3,6,17-21], the any-drug-resistant TB rate was 15.0% to 
20.4%, the monodrug-resistant TB rate was 6.4% to 
17.6%, the MDR TB rate was 4.4% to 13.2%, and the XDR 
TB rate was 0.5% to 1.4%. In addition, MDR TB account-
ed for 2.9% to 5.1% of new cases and 9.3% to 41.8% of 
previously treated cases, whereas XDR TB accounted for 
0.3% to 1.1% of new cases and 2.2% to 47.3% of previously 
treated cases. These studies show that any-drug-resis-
tant and MDR TB decreased from 2001 to 2006. How-
ever, no definitive trend was observed for the gradual 
decrease from 2007 to 2008.
In our study, the any-drug-resistant TB rate was 19.4%, 
the monodrug-resistant TB rate was 18.4%, the MDR TB 
rate was 8.3%, and the XDR TB rate was 3.2%. In addition, 
any-drug-resistant TB accounted for 17.0% of new cases 
and 31.5% of previously treated cases. Monodrug-resis-
tant TB accounted for 15.8% of new cases and 31.2% of 
previously treated cases. MDR TB accounted for 5.8% of 
new cases and 20.1% of previously treated cases. Finally, 
XDR TB accounted for 2.0% of new cases and 8.6% of 
previously treated cases. Although the drug-resistance 
trend among all TB cases did not decline remarkably 
over the study period, except XDR TB, the proportions 
of MDR and XDR TB decreased gradually among previ-
ously treated cases. This observation could be a result of 
the significant increase in the proportion of relapse cas-
es and a decrease in the proportion of TAI cases during 
the study period. Because the drug-resistance rate is 
much higher in TAI cases than that in relapse cases, it 
may have affected the gradual decrease in the drug-re-
sistance rate of the previously treated cases.
Although drug-resistant TB is a critical determinant 
of treatment success in a TB control program, few stud-
ies have compared the drug-resistance pattern of PTB 
with that of EPTB. In addition, three studies have re-
ported that MDR TB occurs less frequently in EPTB 
Table 3. Resistance to anti-tuberculosis drugs according to tuberculosis treatment history
Drugs Total case (n = 1,745) New case (n = 1,431) Previously treated case (n = 314) p value
Any drug-resistance 338 (19.4) 239 (17.0) 99 (31.5) < 0.001
Monodrug-resistance 321 (18.4) 223 (15.8)  98 (31.2) < 0.001
MDR 145 (8.3)  82 (5.8)  63 (20.1) < 0.001
XDR  55 (3.2)  28 (2.0) 27 (8.6) < 0.001
Isoniazid 270 (15.5) 180 (12.6)  90 (28.7) < 0.001
Rifampicin 163 (9.3) 96 (6.7)  67 (21.3) < 0.001
Rifabutin 122 (7.0) 69 (4.8)  53 (16.9) < 0.001
Ethambutol 117 (6.7)  71 (5.0)  46 (14.6) < 0.001
Pyrazinamide 75 (4.3)  41 (2.9)  34 (10.8) < 0.001
Capreomycin 29 (1.7)  21 (1.5)  8 (2.5) 0.218
Kanamycin 39 (2.2)  24 (1.7)  15 (4.8) 0.002
Amikacina 22 (1.3)  16 (1.2)  6 (2.0) 0.263
Streptomycin 95 (5.4) 67 (4.7)  28 (8.9) 0.004
Moxifloxacin 41 (2.4)  23 (1.6)  18 (5.7) < 0.001
Levofloxacinb 31 (2.2)  21 (1.8)  10 (4.0) 0.002
Ofloxacin 51 (2.9) 30 (2.1) 21 (67) < 0.001
Prothionamide 45 (2.6)  24 (1.7)  21 (6.7) < 0.001
Cycloserine 12 (0.7)   8 (0.6)  4 (1.3) 0.245
PAS 74 (4.2) 50 (3.5)  24 (7.6) 0.002
Values are presented as number (%).
MDR, multidrug-resistance; XDR, extensively drug-resistance; PAS, para-aminosalicylic acid.
aAmikacin sensitivity testing was performed in 1,575 cases, including 1,288 new cases and 288 previously treated cases. 
bLevofloxacin sensitivity testing was performed in 1,357 cases, including 1,109 new cases and 249 previously treated cases.
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Table 4. Resistance to anti-tuberculosis drugs according to previously treated cases of relapse, TAI, and TAF (n = 314)
Drugs Relapse (n = 254) TAI (n = 48) TAF (n = 12) p value
Any drug-resistance  56 (22.0) 31 (64.6) 12 (100.0) < 0.001
Monodrug-resistance   55 (21.7) 31 (64.6) 12 (100.0) < 0.001
MDR  24 (9.4)  27 (56.3) 12 (100.0) < 0.001
XDR  5 (2.0)  14 (29.2) 8 (66.7) < 0.001
Isoniazid  47 (18.5)  31 (64.6) 12 (100.0) < 0.001
Rifampicin  28 (11.0)  27 (56.3) 12 (100.0) < 0.001
Rifabutin  21 (8.3) 21 (43.8) 11 (91.7) < 0.001
Ethambutol 18 (7.1) 19 (39.6) 9 (75.0) < 0.001
Pyrazinamide 15 (5.9)  14 (29.2) 5 (41.7) < 0.001
Capreomycin 1 (0.4) 4 (8.3) 3 (25.0)    0.001
Kanamycin 2 (0.8)  8 (16.7) 5 (41.7) < 0.001
Amikacina 0 4 (8.3) 2 (16.7) < 0.001
Streptomycin  12 (4.7)  8 (16.7)  8 (66.7) < 0.001
Moxifloxacin 4 (1.6)  9 (18.8) 5 (41.7) < 0.001
Levofloxacinb 3 (1.2)  9 (18.8) 4 (33.3) < 0.001
Ofloxacin  5 (2.0)  10 (20.8) 6 (50.0) < 0.001
Prothionamide 8 (2.4)  10 (20.8) 5 (41.7) < 0.001
Cycloserine 0 2 (4.2) 2 (16.7)    0.012
PAS  8 (3.1)  11 (22.9) 5 (41.7) < 0.001
Values are presented as number (%).
TAI, treatment after interruption; TAF, treatment after failure; MDR, multidrug-resistance; XDR, extensively drug-resistance; 
PAS, para-aminosalicylic acid.
aAmikacin sensitivity testing was performed in 288 cases. 
bLevofloxacin sensitivity testing was performed in 249 cases.
Figure 2. Trends in resistance rates to anti-tuberculosis drugs among Mycobacterium tuberculosis strains according to treatment 
history from all 2006 to 2013 cases. (A) New cases, (B) previously treated cases. All drug-resistance rates are the same as the 
monodrug-resistance rate, except in 2011.
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cases than it does in PTB cases [9,10,22]. Thus, we com-
pared the pattern of drug-resistance in EPTB with that 
observed in PTB. However, we found no difference in 
the drug-resistance rate between PTB and EPTB accord-
ing to previous treatment status. 
MDR TB was less frequent among patients with EPTB 
than it was among those with PTB, which was similar 
to results reported previously. However, the drug-re-
sistance rates of almost all anti-TB drugs, except that 
of Rfb, were not different. In reports from Taiwan and 
Russia [10,22], the monodrug-resistance rate in patients 
with EPTB was also significantly lower than that in pa-
tients with PTB. 
A possible explanation for this finding is that all cases 
were culture-confirmed cases. Thus, it was possible that 
Table 5. Resistance to anti-tuberculosis drugs according to pulmonary/extrapulmonary tuberculosis and tuberculosis treat-
ment history
Drugs
New case (n = 1,431) Previously treated case (n = 314)
PTB
(n = 1,314)
EPTB
(n = 117)
p value
PTBa
(n = 296)
EPTBb
(n = 18)
p value
Any drug-resistance 219 (16.7) 20 (17.1) 0.897 95 (32.1) 4 (22.2) 0.446
Monodrug-resistance 203 (15.4) 20 (17.1) 0.597 94 (31.8) 4 (22.2) 0.448
MDR  78 (5.9)  4 (3.4) 0.403 62 (20.9)  1 (5.6) 0.138
XDR  26 (2.0)  2 (1.7) 1.000 27 (9.1)  0 0.382
Isoniazid  165 (12.6)   15 (12.8) 0.885  87 (29.4)  3 (16.7) 0.296
Rifampicin  90 (6.8)  6 (5.1) 0.567 66 (22.3)  1 (5.6) 0.136
Rifabutin  66 (5.0)   3 (2.6) 0.363  53 (17.9) 0 0.051
Ethambutol  65 (4.9)  6 (5.1) 0.825 45 (15.2)  1 (5.6) 0.489
Pyrazinamide  37 (2.8)  4 (3.4) 0.569  32 (10.8) 2 (11.1)  1.000
Capreomycin  19 (1.4)  2 (1.7) 0.686 8 (2.7) 0 1.000
Kanamycin 22 (1.7)  2 (1.7) 1.000 15 (5.1) 0 1.000
Amikacinc  16 (1.2)  0 0.635  6 (2.0) 0 1.000
Streptomycin 62 (4.7)  5 (4.3) 1.000 27 (9.1) 1 (5.6) 1.000
Moxifloxacin  21 (1.6)  2 (1.7) 0.710 18 (6.1) 0 0.611
Levofloxacind  25 (1.9)  2 (1.7) 1.000 16 (5.4) 0 0.611
Ofloxacin 28 (2.1)  2 (1.7) 1.000 21 (7.1) 0 0.387
Prothionamide 22 (4.7)  2 (1.7) 1.000 21 (7.1) 0 0.387
Cycloserine    8 (0.6)  0 1.000 4 (1.4) 0 1.000
PAS 46 (3.5)   4 (3.4) 1.000 23 (7.8)  1 (5.6) 1.000
Values are presented as number (%).
PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis; MDR, multidrug-resistance; XDR, extensively drug-resis-
tance; PAS, para-aminosalicylic acid.
aPTB included relapse (n = 237), TAI (n = 47), and TAF (n = 12).
bEPTB included relapse (n = 17) and TAI (n = 1).
cAmikacin sensitivity testing was performed in 1,575 cases, including 1,455 new cases and 120 previously treated cases. 
dLevofloxacin sensitivity testing was performed in 1,357 cases, including 1,259 new cases and 99 previously treated cases.
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Figure 3. Trend in the proportion of relapse, treatment after 
interruption (TAI), and treatment after failure (TAF) cases 
among previously treated cases from 2006 to 2013.
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many drug-sensitive EPTB cases were excluded. In an 
actual clinical setting, many EPTB cases are diagnosed 
without culture because isolating M. tuberculosis from an 
EPTB site is difficult, although the WHO recommends 
culturing specimens from a suspected extrapulmonary 
site. In fact, the proportion of EPTB cases among all 
TB cases was lower (7.7%) in our study than the 21.8% 
reported in the USA, the 27.5% reported in Russia, and 
the 21.4% reported in Taiwan [9,10,22]. Another possi-
ble explanation is that the proportion of drug-resistant 
strains of infectious TB bacilli in a community affects 
similar drug-resistance to PTB and EPTB. In contrast, 
another possible explanation is that studies conducted 
outside Korea were based on the specimen site, without 
considering concurrent EPTB and PTB [10]. In addition, 
another study excluded cases of concurrent EPTB and 
PTB [9]. In our study, we classified pulmonary and EPTB 
separately, as recommended by the WHO [12], although 
we found few concurrent EPTB and PTB cases (n = 45). 
This study had several limitations. First, it was per-
formed in a single tertiary referral center; thus, the re-
sults may not reflect the overall situation in South Ko-
rea. Second, a lack of information regarding the DST 
for previous TB infections in the previously treated TB 
cases precluded ascertaining whether drug-resistance 
was attributable to inadequate or incomplete treat-
ment or whether it was the result of a previous infec-
tion with a resistant strain. We attempted to obtain past 
DST records of previously treated cases via the public 
health center; however, many of these records could not 
be traced. Third, some previously treated cases in the 
private sector may have been misclassified as new cas-
es. Moreover, new drug-resistant patients may have a 
greater tendency to visit a tertiary hospital, which may 
have affected our results, as the new drug-resistant and 
MDR rates were higher than those reported from public 
health centers. 
In conclusion, the TB drug-resistance rate, particu-
larly that of MDR TB, remains high at a private refer-
ral hospital, and the drug-resistance rate did not de-
crease significantly from 2006 to 2013. However, the 
proportions of MDR and XDR TB cases since 2006 are 
suspected to have decreased consistently among previ-
ously treated cases. This finding may be a result of the 
significant increase in the proportion of relapse cases 
and a decrease in the proportion of TAI cases over time. 
In addition, we found no remarkable difference in the 
drug-resistance rate between PTB and EPTB. Howev-
er, a national survey of the prevalence of drug-resistant 
TB should be conducted to obtain the most accurate 
drug-resistance status in South Korea, including the 
private sector. However, this will require a vast amount 
of time and financial investment.
KEY MESSAGE
1. The tuberculosis (TB) drug-resistance rate, 
particularly that of multidrug-resistant TB, 
remains high at a private referral hospital, and 
the drug-resistance rate did not decrease sig-
nificantly from 2006 to 2013.
2. No remarkable difference in the drug-resistance 
rate was observed between pulmonary tubercu-
losis and extrapulmonary tuberculosis.
Table 6. Distribution of resistance to anti-tuberculosis drugs among new cases of pulmonary tuberculosis according to age group
Age, yr Number Any drug-resistance Monodrug-resistance MDR XDR
Total 1,314 219 (16.7)  203 (15.4) 78 (5.9) 26 (2.0)
10–19 18 1 (5.6)  1 (5.6) 0 0
20–29 165 25 (15.2) 24 (14.5)   7 (4.2)   1 (0.6)
30–39 177 32 (18.1) 29 (16.4) 10 (5.6)   5 (2.8)
40–49 173 30 (17.3) 28 (16.2) 12 (6.9)  6 (3.5)
50–59 222  45 (20.3) 41 (18.5) 19 (8.6)  4 (1.8)
60–69 195  37 (19.0)  35 (17.9) 15 (7.7)  4 (2.1)
≥ 70 364 49 (13.5)  45 (12.4) 15 (4.1)  6 (1.6)
Values are presented as number (%).
MDR, multidrug-resistance; XDR, extensively drug-resistance.
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